SmartCella

Procella Therapeutics is an early-stage biotechnology company developing cell-based therapies for patients with advanced heart failure. Its work centers on cardiac progenitor cells derived from pluripotent stem cells, designed to regenerate muscle damaged by heart disease. The company advances regenerative-medicine programs toward first-in-human studies, supported by cell-therapy manufacturing, quality-control, and translational-development capabilities within the SmartCella group in Sweden and internationally.